A pellet having a convex shaped front includes a plurality of radially disposed surface slots. The concave shaped rear portion has a matching number of surface ribs that can be frictionally attached to the convex portion's slots. The pellet is constructed of a combination of medical compounds along with appropriate binders and other compounds that are pressed together under high pressure to produce a rigid mass capable of being propelled at high speeds and to pierce the skin of an animal or person where the compounds can be dissolved when contacting the internal liquid portion of the animal or person. The pellet can be loaded and propelled by a standard air rifle, gun, or pistol.

The invention provides gastric residence systems for administration of adamantane-class drugs or pharmaceutically acceptable salts thereof, such as memantine or pharmaceutically acceptable salts thereof, and methods for making and using such systems. The systems provide extended release of drug, reducing the frequency with which the drug must be administered to the patient. The gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, can have release rate-modulating films, which provide good control over release of adamantane-class drugs or pharmaceutically acceptable salts thereof present in the gastric residence system. Some embodiments of the films can provide resistance against burst release of adamantane-class drugs or pharmaceutically acceptable salts thereof upon exposure to alcohol.

The subject invention pertains to methods to produce amorphous materials at nanometer scale, by solidifying or hardening the materials inside nanometer-sized pores of porous media (i.e., porous templates). The porous templates can be made by packing nanometer-sized particles or other means. The subject invention further pertains to methods to produce the porous templates used to produce amorphous material at nanometer scale.

This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders.

The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.

Nutraceutical composition for the activation of sirtuins in humans, the composition including from 10% by weight to 15% by weight of honokiol; from 12% by weight to 40% by weight of pterostilbene; from 22% by weight to 32% by weight of polydatin; from 25% by weight to 40% by weight of ellagic acid and from 1.5% by weight to 3% by weight of a mixture of zinc, seleniun, chromium and nicotinamide, the composition promoting the inhibition of cell degradation and aging phenomena.

Provided is a solid preparation comprising a controlled-release film, wherein the controlled-release film includes a dry film of an edible ink, and contains a water-insoluble polymer, and has excellent controlled-releasability of an active ingredient contained in a tablet core. The solid preparation according to the present invention comprises a tablet core, and at least one layer of a controlled-release film provided on at least a part of a surface of the tablet core, wherein the tablet core contains at least one active ingredient, and the controlled-release film includes a dry film of an edible ink containing at least one water insoluble polymer.

This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.

A multi-unit pharmaceutical composition comprising an immediate release component comprising a polyphenol-containing Aspalathus linearis extract and one or more pharmaceutically acceptable excipients, and a sustained release component comprising a polyphenol-containing Aspalathus linearis extract and one or more pharmaceutically acceptable excipients, wherein the composition provides a substantially linear polyphenol release profile over a predetermined period, for example about 8 hours.